Stay updated on BMS-986036 Clinical Trial in NASH Cirrhosis
Sign up to get notified when there's something new on the BMS-986036 Clinical Trial in NASH Cirrhosis page.

Latest updates to the BMS-986036 Clinical Trial in NASH Cirrhosis page
- Check4 days agoChange DetectedUpdated revision to v3.0.2 and removed the Back to Top element; no core content or critical information is affected.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as additional medical topics related to liver diseases and drug safety. Notably, the revision number has changed to v3.0.0, indicating a significant update.SummaryDifference5%
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe webpage has added a new clinical study for an experimental medication, BMS-986036, aimed at treating Nonalcoholic Steatohepatitis (NASH) and liver cirrhosis, along with detailed information about the study's design, eligibility criteria, and locations. Additionally, the page now includes a disclaimer regarding the U.S. government's non-review of all studies listed.SummaryDifference100%
Stay in the know with updates to BMS-986036 Clinical Trial in NASH Cirrhosis
Enter your email address, and we'll notify you when there's something new on the BMS-986036 Clinical Trial in NASH Cirrhosis page.